BTF Best of ASH and SABCS 2024, Houston

Houston, TX US
January 19, 2024 to January 20, 2024

The BTF Best of ASH & SABCS 2024, Houston, is a CME-accredited, in-person hematology oncology conference featuring leading hematology and breast cancer experts. Expert faculty will place key abstract findings from the 65th ASH Annual Meeting (ASH2023) and the San Antonio Breast Cancer Symposium (SABCS2023) into clinical context and discuss how the results may change the current standards of care for patients with benign and malignant hematologic disorders and breast cancer. This conference is designed to provide physicians, physician assistants, nurse practitioners, pharmacists, nurses, and other healthcare professionals with the latest updates in the field. It will highlight a multidisciplinary approach and the integration of new advances in patient-centered care.

This conference allows attendees an opportunity to discuss current research and advances in the field of hematologic disorders and breast cancer with colleagues and key opinion leaders. The goals of this conference are to review and critically assess the results of practice-changing clinical data and expert recommendations to optimize clinical outcomes for patients. 

Target Audience

  • Hematologists, Oncologists
  • Surgeons
  • Radiation Oncologists
  • Physician Assistants/Nurse Practitioners
  • Pharmacists
  • Nurses

Organizing Committee

Conference Director:

Binay Shah, MD, MHA - Binaytara Foundation

Co Chairs:

Rachel Layman, MD - MD Anderson Cancer Center

Shilpan Shah, MD - Houston Methodist

Planning Committee

Eleanor Hobaugh, PharmD, BCOP - Houston Methodist

VENUE INFORMATION

A limited number of rooms have been booked at the Hyatt Regency Houston/Galleria for attendees and sponsors of this meeting at a discounted rate of $155/night. Please book your room early to take advantage of the discounted rate. The cut off date is Wednesday, January 3, 2024.

Learning Objectives

  1. Review data presented at the ASH2023 and SABCS2023 & discuss their applications in clinical settings.    
  2. Choose new therapeutic options for treating benign and malignant hematologic disorders & breast cancer, understanding appropriate indications and contraindications to these therapeutic approaches.
  3. Discuss the study design and primary endpoints of recently reported and ongoing trials that have influenced the changes in the standards of care in hematology and breast cancer.
  4. Integrate evolving diagnostic, prognostic, and therapeutic approaches to managing hematologic disorders and breast cancer patients.
  5. Individualize management of patients based on emerging data from clinical trials and evolving expert guidelines.

GLOBAL ONCOLOGY PROJECT

To learn more about our ongoing project building a 200-bed cancer hospital in Nepal:

Course summary
Available credit: 
  • 8.50 ABIM MOC II
    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 8.50 Medical Knowledge points in the American Board of Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
  • 8.50 AMA PRA Category 1 Credit™
    The Binaytara Foundation is accredited by the Washington State Medical Association to provide continuing medical education for physicians. The Binaytara Foundation designates this live activity for a maximum of 8.50 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. This activity meets the criteria for up to 8.50 hours of Category I CME credit to satisfy the relicensure requirements of the Washington State Medical Quality Assurance Commission.
  • 8.50 Nursing Contact Hours
    Provider approved by the California Board of Registered Nursing, Provider # CEP17035, for 8.50 Contact Hours.
Course opens: 
10/20/2023
Course expires: 
07/01/2024
Event starts: 
01/19/2024 - 5:00pm PST
Event ends: 
01/20/2024 - 4:35pm PST
Cost:
$150.00

DAY 1 – January 19th, 2024

All times are listed in Central Standard Time (CST)

03:00 PM – 03:55 PM: Registration/Networking & Exhibits


03:55 PM – 04:00 PM: Opening Remarks


04:00 PM – 05:00 PM: Session 1

Moderator: Solange Cox, MD

04:00 PM – 04:20 PM: Radiotherapy – Best Breast Practice - Simona Shaitelman, MD, EdM

04:20 PM – 04:40 PM: Updates in Surgical Approach – Best Breast Practice -Taiwo Adesoye, MD, MPH 

04:40 PM – 05:00 PM: Q & A


05:00 PM – 06:30 PM: Session 2 – Case-Based Discussion

Moderator: Lawrence Rice, MD

Case 1 – Bleeding Disorder - Akhil Mehta, DO, MPH

Case 2 – Clotting Disorder - Vahid Afshar-Kharghan, MD

Case 3 – ITP/TTP - Shubham Adroja, MD

Case 4 – Anemia - Ethan Burns, MD

Case 5 – Bone Marrow Failure - Vikram Dhillon, DO, MBA

Panel: Eleanor Hobaugh, PharmD, BCOP


06:30 PM – 07:15 PM: Networking/Reception & Exhibits


DAY 2 – January 20th, 2024

07:00 AM – 07:55 AM: Breakfast & Exhibits


07:55 AM – 08:10 AM: Binaytara Foundation - Binay Shah, MD, MHA


08:10 AM – 09:40 AM: Session 3

Moderators: Shilpan Shah, MD; Martha Mims, MD, PhD

08:10 AM – 08:35 AM: MDS/Acute Leukemia - Martha Mims, MD, PhD

08:35 AM – 09:00 AM: Myeloproliferative Neoplasms and CML - Shilpan Shah, MD

09:00 AM – 09:25 AM: Cellular Therapy in Hematologic Malignancies – Recent Updates - Sai Ravi Pingali, MD

09:25 AM – 09:40 AM: Q & A


09:40 AM – 10:00 AM:  Break & Exhibits


10:00 AM – 11:45 AM: Session 4

Moderator: Tejo N. Musunuru, MD

10:00 AM – 10:25 AM: Lymphoma - Sravanti Teegavarapu, MD

10:25 AM – 10:50 AM: Chronic Lymphocytic Leukemia - Alessandra Ferrajoli, MD

10:50 AM – 11:15 AM: Multiple Myeloma - Carrie Yuen, MD

11:15 AM – 11:45 AM: Q & A


11:45 AM – 12:45 PM: Lunch & Exhibits


12:45 PM – 02:30 PM: Session 5

Moderator: Michelina Cairo, MD

12:45 PM – 01:10 PM: Hormone Receptor Positive Breast Cancer - Rachel Layman, MD

01:10 PM – 01:35 PM: HER2 Positive Breast Cancer - Darya Kizub, MD

01:35 PM – 02:00 PM: Triple Negative and HER2 Low Breast Cancer - Akshjot Puri, MD

02:00 PM – 02:30 PM: Q & A


02:30 PM – 03:30 PM: Session 6 – Case-Based Discussion

Moderator: Carlos Barcenas, MD, MSc

Case 1 – DCIS - Ahmed Elkhanany, MD

Case 2 – Inflammatory Breast Cancer - Azadeh Nasrazadani, MD, PhD

Case 3 – Metaplastic Breast Cancer - Polly Niravath, MD


03:30 PM: Adjourn

Hyatt Regency Houston/Galleria
2626 Sage Road
Houston, TX 77056
United States
+1 (832) 803-1234

A limited number of rooms have been booked at the Hyatt Regency Houston/Galleria for attendees and sponsors of this meeting at a discounted rate of $155/night. Please book your room early to take advantage of the discounted rate. The cut off date is Wednesday, January 3, 2024.

IDENTIFICATION AND MITIGATION OF POTENTIAL CONFLICT OF INTERESTS:

All conflict of interest has been identified and mitigated for individuals in control of contents.

PLANNING COMMITTEE DISCLOSURE STATEMENT:

None of the members of the planning committee, nor any member of their immediate families, have a relevant financial interest in or affiliation with any commercial supporter of this educational activity and/or with the manufacturer(s) of commercial products and/or providers of any commercial services discussed in this educational activity.

Course Director(s)

Binay Shah, MD, MHA

has no relevant financial relationships to disclose at this time.
Conference Chair(s)

Rachel Layman, Rachel M. Layman, MD. Professor, Breast Medical Oncology, MD Anderson Cancer Center

has a financial relationship (Grant Or Contract) with Accutar Biotechnology;.
has a financial relationship (Independent contractor) with Pfizer;.
has a financial relationship (Grant Or Contract) with Arvinas;.
has a financial relationship (Independent contractor) with Eli Lilly;.
has a financial relationship (Grant Or Contract) with Pfizer;.
has a financial relationship (Grant Or Contract) with Celcuity;.
has a financial relationship (Grant Or Contract) with Eli Lilly;.
has a financial relationship (Independent contractor) with Novartis;.
has a financial relationship (Grant Or Contract) with Zentalis;.
has a financial relationship (Independent contractor) with Biotheryx;.
has a financial relationship (Grant Or Contract) with Novartis;.
has a financial relationship (Grant Or Contract) with Puma;.
has a financial relationship (Independent contractor) with Gilead;.

Shilpan Shah

has no relevant financial relationships to disclose at this time.
Speaker/Topic Presenter(s)

Taiwo Adesoye, MD, MPH

has no relevant financial relationships to disclose at this time.

Alessandra Ferrajoli, MD, Professor

has a financial relationship (Other) with Astra-Zeneca;.
has a financial relationship (Other) with Abbvie;.
has a financial relationship (Other) with Johnson & Johnson;.
has a financial relationship (Other) with Beigene;.

Darya Kizub, MD

has no relevant financial relationships to disclose at this time.

Martha Mims

has a financial relationship (Grant Or Contract) with Aveo;.
has a financial relationship (Grant Or Contract) with Celgene;.
has a financial relationship (Stock) with Biogen IDEC;.
has a financial relationship (Grant Or Contract) with Incyte;.
has a financial relationship (Stock) with Amgen;.

Sai Ravi Pingali

has a financial relationship (Professional Services) with Cardinal Health;.

Akshjot Puri, MD

has no relevant financial relationships to disclose at this time.

Simona Shaitelman

has a financial relationship (Grant Or Contract) with Artidis;.
has a financial relationship (Other) with Lumicell;.
has a financial relationship (Other) with BD;.
has a financial relationship (Grant Or Contract) with ExactSciences;.

Sravanti Teegavarapu

has no relevant financial relationships to disclose at this time.

Carrie Hau Lai Yuen, MD

has no relevant financial relationships to disclose at this time.
Case Presenter(s)

Shubham Adroja

has no relevant financial relationships to disclose at this time.

Vahid Afshar-Kharghan, MD

has no relevant financial relationships to disclose at this time.

Ethan Burns, MD

has no relevant financial relationships to disclose at this time.

Vikram Dhillon, DO, MBA

has no relevant financial relationships to disclose at this time.

Ahmed Elkhanany, MD

has a financial relationship (Other) with Biotheranostics;.

Akhil Mehta

has no relevant financial relationships to disclose at this time.

Azadeh Nasrazadani, MD PhD

has a financial relationship (Professional Services) with Astra Zeneca;.
has a financial relationship (Professional Services) with Novartis;.

Polly Niravath, MD

has no relevant financial relationships to disclose at this time.
Moderator(s)

Carlos Barcenas, MD, MSc

has no relevant financial relationships to disclose at this time.

Michelina Cairo

has a financial relationship (Professional Services) with Novartis;.
has a financial relationship (Professional Services) with Astra Zeneca/Daiichi Sankyo;.
has a financial relationship (Professional Services) with Gilead Sciences;.

Solange Cox, MD

has no relevant financial relationships to disclose at this time.

Tejo Musunuru, MD

has no relevant financial relationships to disclose at this time.

Lawrence Rice

has a financial relationship (Professional Services) with Takeda;.
has a financial relationship (Professional Services) with Novartis;.
has a financial relationship (Professional Services) with Agios;.
has a financial relationship (Professional Services) with Alexion;.
Planning committee(s)

Eleanor Hobaugh, PharmD, BCOP

has no relevant financial relationships to disclose at this time.

Available Credit

  • 8.50 ABIM MOC II
    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 8.50 Medical Knowledge points in the American Board of Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
  • 8.50 AMA PRA Category 1 Credit™
    The Binaytara Foundation is accredited by the Washington State Medical Association to provide continuing medical education for physicians. The Binaytara Foundation designates this live activity for a maximum of 8.50 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. This activity meets the criteria for up to 8.50 hours of Category I CME credit to satisfy the relicensure requirements of the Washington State Medical Quality Assurance Commission.
  • 8.50 Nursing Contact Hours
    Provider approved by the California Board of Registered Nursing, Provider # CEP17035, for 8.50 Contact Hours.

If you are interested in exhibiting at this meeting, please visit our exhibit page here - https://education.binayfoundation.org/exhibit-information

 

Price

Cost:
$150.00
Please login or register to take this course.

POLICY ON INDUSTRY EMPLOYEE'S PARTICIPATION IN MARKETING/EDUCATION ACTIVITY AT THE CONFERENCE: 

All marketing and product promotion activities must occur in the designated exhibit hall or product theater space separate from the area where this accredited continuing education takes place. 

The exhibit and product promotion space is reserved only for companies that have purchased marketing and product promotion slots at the conference.  The individual registration fee doesn't include marketing or product theater privileges. Please refer to the sponsorship handbook for the types of marketing activities included in your display/sponsorship fees. 

If your company has NOT purchased a marketing opportunity such as an exhibit table, product theater slot or another type of marketing opportunity, you may not participate in any marketing activity or attempt to educate healthcare providers about your product or service. Industry attendees of companies without marketing opportunities must refrain from interacting with healthcare providers at this meeting in any form, including introducing themselves as an employee of the company, discussing the care of patients, handing out flyers and brochures, inviting participants to the company's other programs, etc.

Violating this policy will result in a fine equivalent to a general display fee for that conference. 

 

NOTICE TO HCPS EMPLOYED BY THE INDUSTRY:

If you are employed by industry, including pharmaceuticals and biotech companies, you must pay the INDUSTRY REGISTRATION FEE to participate in any meeting organized by the Binaytara Foundation. If you misrepresented yourself as a healthcare provider not employed by the industry and failed to pay the Industry registration fee, the following fees apply:

  • If your company has purchased a display table at the event, you will be billed the full INDUSTRY REGISTRATION FEE plus a fine equivalent to the full industry registration fee for that event = 2 X the industry registration fee.
  • If your company has NOT purchased a display table at the event AND you attended the meeting without paying a full industry registration fee, you will be billed a full GENERAL DISPLAY FEE for that event. 
  • If your company has NOT purchased a display table at the event AND you attended the meeting paying a full industry registration fee, BUT YOU PARTICIPATED IN MARKETING AND PROMOTIONAL ACTIVITIES, you will be billed a full GENERAL DISPLAY FEE for that event. 

Any outstanding display fee, registration fee, and fines must be paid before the industry employee or the company will be able to attend/display at our conferences again.

CANCELLATION POLICY

You may cancel your enrollment at any time. Cancellation fees apply as below:

  • 50% of the paid registration fee will be refunded if registration is canceled six weeks before the conference.
  • No refunds will be issued if registration is canceled after that date.  

No credits will be offered if you do not complete all required steps of this activity, including registration and participation in the live meeting.